Indian Myasthenia Gravis Therapeutics Market size stood at around USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period.
Myasthenia gravis (MG) is one of the rare, chronic, progressive neuromuscular disorder which has symptoms like weakness of the head, limb, spinal, eye, and respiratory muscles, double vision, facial paralysis, difficulty in walking, dropping of eyelids. This disease can be diagnosed by tests such as repetitive nerve stimulation test, blood test for antibodies, edrophonium test, Computed Tomography (CT), and Magnetic Resonance Imaging (MRI). Corticosteroids drugs (azathioprine, and cyclosporine) and Acetylcholine esterase inhibitors (Edrophonium, and Pyridostigmine) are used for the treatment of MG. In this disorder, antibodies can be produced against the acetylcholine receptor (AchR) that impedes normal transmission of electrical signals from nerves to muscles.
The Myasthenia Gravis market is accepted to grow in the forecast, owing to the factors like rising healthcare expenditure, growing occurrence of autoimmune disorder improving healthcare infrastructure, and massive investment, many drugs are in pipeline under clinical development phases which can be approved in future. Rapidly rising population with myasthenia gravis in India and serving the untapped geriatric population with autoimmune disease creates lucrative opportunity in the myasthenia gravis market